| Literature DB >> 35966519 |
Emma B N J Janssen1,2, Mieke C E Hooijschuur1, Veronica A Lopes van Balen1, Erjona Morina-Shijaku1, Julia J Spaan1, Eva G Mulder1, Arnold P Hoeks3, Koen D Reesink2,3, Sander M J van Kuijk4, Arnoud Van't Hof2,5,6, Bas C T van Bussel7,8, Marc E A Spaanderman1,9, Chahinda Ghossein-Doha1,2,5.
Abstract
Introduction: Preeclampsia, an endothelial disorder of pregnancy, predisposes to remote cardiovascular diseases (CVD). Whether there is an accelerated effect of aging on endothelial decline in former preeclamptic women is unknown. We investigated if the arterial aging regarding endothelial-dependent and -independent vascular function is more pronounced in women with a history of preeclampsia as compared to women with a history of solely normotensive gestation(s).Entities:
Keywords: aging; arterial function; cardiovascular; endothelial (dys)function; flow-mediated dilation (FMD); hypertensive pregnancy; preeclampsia
Year: 2022 PMID: 35966519 PMCID: PMC9371444 DOI: 10.3389/fcvm.2022.911603
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Flowchart of inclusion study population. FMD, flow-mediated-dilation; NGMD, nitroglycerine-mediated dilation.
Baseline characteristics of entire study population and stratified for history of preeclampsia.
|
|
|
|
| |
|---|---|---|---|---|
| Age (years) | 40.5 ± 8.6 | 38.5 ± 7.9 | 44.5 ± 8.4 |
|
| Parity | 2 [1–2] | 2 [1–2] | 2 [2–3] |
|
| Early onset PE | 411 (33.8%) | 411 (51.2%) | N.A. | N.A. |
| HELLP-syndrome | 567 (46.6%) | 567 (70.6%) | N.A. | N.A. |
| Months postpartum | 104 [28–198] | 71 [17–155] | 180 [91–272] |
|
| Postmenopausal | 176 (14.6%) | 78 (9.8%) | 98 (23.9%) |
|
| BMI (kg/m2) | 25.3 ± 4.6 | 25.7 ± 4.8 | 24.8 ± 4.1 |
|
| Current smoking | 85 (7.0%) | 46 (5.7%) | 39 (9.4%) |
|
| Positive CVD family history | 723 (59.8%) | 493 (61.9%) | 230 (55.7%) |
|
| Diabetes Mellitus | 13 (1.1%) | 12 (1.5%) | 1 (0.2%) | 0.072 |
| Hypertension | 143 (11.8%) | 114 (14.2%) | 29 (7.0%) |
|
| Antihypertensive drugs use | 113 (9.3%) | 90 (11.2%) | 23 (5.6%) |
|
| Multivitamin use | 331 (27.2%) | 205 (25.5%) | 126 (30.4%) | 0.077 |
| Glucose level (mmol/L) | 5.1 ± 0.8 | 5.2 ± 0.9 | 5.0 ± 0.5 |
|
| Systolic BP (mmHg) | 113 [107–122] | 115 [108–123] | 111 [105–118] |
|
| Diastolic BP (mmHg) | 71 [66–77] | 73 [67–79] | 69 [64–74] |
|
| MAP (mmHg) | 87 [82–94] | 89 [83–96] | 84 [79–90] |
|
| Baseline brachial artery diameter (mm) | 3.53 ± 0.44 | 3.50 ± 0.43 | 3.60 ± 0.46 |
|
| Absolute FMD (mm) | 0.14 [0.09–0.21] | 0.14 [0.09–0.20] | 0.14 [0.09–0.21] | 0.846 |
| Relative FMD (%) | 3.9 [2.5–5.9] | 3.9 [2.5–5.9] | 3.9 [2.4–5.9] | 0.514 |
| Allometric FMD (%) | 4.0 [2.5–6.0] | 4.0 [2.5–6.0] | 4.0 [2.4–6.1] | 0.514 |
| Absolute NGMD (mm) | 0.59 ± 0.18 | 0.59 ± 0.18 | 0.59 ± 0.19 | 0.921 |
| Relative NGMD (%) | 17.0 ± 5.5 | 17.1 ± 5.5 | 16.8 ± 5.5 | 0.260 |
| Dilation (FMD) in proportion of maximal dilation (NGMD) (%) | 24.3 [14.5–35.8] | 23.8 [14.4–35.8] | 24.5 [14.6–35.9] | 0.962 |
Variable consisted few missing values (<2.0%), valid percentages are presented. Continuous variables are reported as mean ± standard deviation in case of normal distribution, otherwise as median [IQR]. Categorical variables are reported as number (%). Statistically significant p-values are presented in cursive.
PE, preeclampsia; BMI, body mass index; CVD, cardiovascular disease; BP, blood pressure; MAP, mean arterial pressure; FMD, flow-mediated-dilation; NGMD, nitroglycerine-mediated dilation.
Figure 2Brachial artery diameter (mm) across age categories stratified for women with a history of preeclampsia-complicated pregnancy (i.e. preeclampsia) and women with a history of normotensive pregnancy (i.e., controls). Both in women with and without a history of preeclampsia, brachial artery diameter increased with advancing age. Number of inclusions within groups: 20–30 years: preeclampsia n = 103, controls n = 16; 30–40 years: preeclampsia n = 392, controls n = 111; 40–50 years: preeclampsia n = 238, controls n = 159; ≥50 years: preeclampsia n = 70, controls n = 128.
Figure 3Relative FMD (%), allometric FMD (%) and NGMD (%) across age categories stratified for women with a history of preeclampsia-complicated pregnancy (i.e. preeclampsia) and women with a history of normotensive pregnancy (i.e. controls). Both in women with and without a history of preeclampsia, FMD (%), allometric FMD and NGMD (%) decreased with advancing age. Between women with preeclampsia and controls no clear differences were found with regard to FMD (%), allometric FMD (%) and NGMD (%). Number of inclusions within groups: 20–30 years: preeclampsia n = 103, controls n = 16; 30–40 years: preeclampsia n = 392, controls n = 111; 40–50 years: preeclampsia n = 238, controls n = 159, ≥50 years: preeclampsia n = 70, controls n = 128. FMD, flow-mediated-dilation; NGMD, nitroglycerine-mediated dilation.
Trend effect of advancing age on FMD and NGMD.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Brachial artery diameter (mm) | 3.36 ± 0.34 | 3.45 ± 0.40 | 3.57 ± 0.43 | 3.79 ± 0.50 |
|
| FMD | |||||
| Absolute FMD (mm) | 0.16 [0.11–0.22] | 0.15 [0.09–0.21] | 0.13 [0.09–0.20] | 0.12 [0.07–0.18] |
|
| Relative FMD (%) | 4.7 [3.3–6.7] | 4.4 [2.6–6.4] | 3.6 [2.4–5.7] | 3.1 [2.0–5.1] |
|
| Allometric FMD (%) | 4.8 [3.3–6.9] | 4.5 [2.6–6.6] | 3.7 [2.4–5.8] | 3.1 [2.0–5.2] |
|
| NGMD | |||||
| Absolute NGMD (mm) | 0.60 ± 0.16 | 0.61 ± 0.18 | 0.58 ± 0.19 | 0.58 ± 0.20 |
|
| Relative NGMD (%) | 18.1 ± 5.4 | 17.8 ± 5.6 | 16.5 ± 5.2 | 15.4 ± 5.4 |
|
| Dilation (FMD) in proportion of maximal dilation (NGMD) (%) | 27.7 [19.9–36.6] | 24.4 [15.1–36.4] | 23.9 [14.3–35.3] | 20.5 [12.4–34.1] |
|
Continuous variables are reported as mean ± standard deviation in case of normal distribution, otherwise as mean [IQR]. Categorical variables are reported as number (%). Statistically significant p-values are presented in cursive.
yrs, years; FMD, flow-mediated-dilation; NGMD, nitroglycerine-mediated dilation.
Association of age and history of preeclampsia with brachial artery diameter, FMD and NGMD.
|
|
|
| ||||
|---|---|---|---|---|---|---|
| β (95% CI), mm/10 yr | β (95% CI), mm/10 yr | β (95% CI), %/10 yr | ||||
|
| ||||||
| Age (in deciles) | 0.16 (0.13–0.18) |
| −0.01 (−0.02–−0.003) |
| −0.50 (−0.69–−0.32) |
|
| History of PE | −0.01 (−0.07–0.04) | 0.602 | −0.008 (−0.02–0.004) | 0.183 | −0.15 (−0.49–0.19) | 0.381 |
|
| ||||||
| Age (in deciles) | 0.14 (0.10–0.17) |
| −0.01 (−0.01–0.003) | 0.060 | −0.42 (−0.63–−0.21) |
|
| History of PE | −0.06 (−0.12–−0.1) |
| −0.008 (−0.02–0.003) | 0.155 | −0.09 (−0.43–0.25) | 0.598 |
|
|
|
| ||||
| β (95% CI), %/10 yr | β (95% CI), mm/10 yr | β (95% CI), %/10 yr | ||||
|
| ||||||
| Age (in deciles) | −0.52 (−0.72–−0.33) |
| −0.02 (−0.04–−0.01) |
| −1.20 (−1.58–−0.81) |
|
| History of PE | −0.16 (−0.51–0.20) | 0.384 | −0.01 (−0.04–0.01) | 0.282 | −0.36 (−1.05–0.34) | 0.312 |
|
| ||||||
| Age (in deciles) | −0.44 (−0.66–−0.22) |
| −0.02 (−0.03–−0.002) |
| −1.02 (−1.48–−0.56) |
|
| History of PE | −0.09 (−0.44–0.26) | 0.602 | −0.001 (−0.03–0.02 | 0.951 | 0.09 (−0.63–0.81) | 0.806 |
|
| ||||||
| β (95% CI), %/10 yr | ||||||
|
| ||||||
| Age (in deciles) | −1.47 (−2.67to −0.27) |
| ||||
| History of PE | −0.85 (−3.01 to 1.31) | 0.441 | ||||
|
| ||||||
| Age (in deciles) | 1.22 (−2.54 to 0.10) | 0.071 | ||||
| History of PE | −0.87 (−2.97 to 1.24) | 0.417 | ||||
Fully-adjusted models adjusted for BMI, smoking, anti-hypertensive drug use, MAP, fasting glucose levels, menopausal state and family history of CVD. Regression on FMD and NGMD was additionally adjusted for stress stimulus and regression on absolute FMD and absolute FMD for baseline diameter. Statistically significant p-values are presented in cursive.
β, unstandardized regression coefficient; FMD, flow-mediated-dilation; NGMD, nitroglycerine-mediated dilation; 95% CI, 95% confidence interval.